Brand logo Aimovig® (erenumab).
Neuroscience
AIMOVIG® (erenumab)
Brand logo Cosentyx® (secukinumab).
Dermatology
Cosentyx® (secukinumab)
Brand logo Cosentyx® (secukinumab).
Rheumatology
Cosentyx® (secukinumab)
Brand logo Entresto® (sacubitril/valsartan).
Cardio-metabolic
Entresto (sacubitril/valsartan)
Brand logo FABHALTA®▼ (iptacopan).
Haematology
FABHALTA®▼ (iptacopan)
Brand logo ILARIS® (canakinumab).
Immunology
ILARIS® (canakinumab)
Brand logo JAKAVI® (ruxolitinib).
Haematology
JAKAVI® (ruxolitinib)
Kesimpta ofatumumab logo
Neuroscience
KESIMPTA®▼ (ofatumumab)
Brand logo KISQALI® (ribociclib).
Oncology
KISQALI® (ribociclib)
Leqvio inclisiran logo
Cardio-metabolic
LEQVIO® (inclisiran)
Lutathera® (lutetium [177Lu] oxodotreotide) logo
Radiogland
LUTATHERA® (177Lu-DOTATATE)
Brand logo Sandostatin® LAR® (octreotide).
Oncology
SANDOSTATIN® LAR® (octreotide acetate)
Brand logo SCEMBLIX®▼(asciminib).
Haematology
SCEMBLIX®▼ (asciminib)
Brand logo Tafinlar® + Mekinist (dabrafenib + trametinib).
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma
Brand logo Tafinlar® + Mekinist (dabrafenib + trametinib).
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)
Brand logo Xolair® (omalizumab).
Dermatology
XOLAIR® (omalizumab)
Xolair Logo
Respiratory and Inflammation
Xolair® (omalizumab)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.